Emerging Paediatric Uses of Dupilumab Beyond Approvals
Clinical & Experimental Allergy · 2026-10 · 56 (10) · 1162-1176
DOI: 10.1111/cea.70381 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 23.06.2026. Verfasst von Simone Foti Randazzese und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Unit, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dupilumab is a fully human IgG4 monoclonal antibody that targets the interleukin‐4 receptor alpha subunit, thereby inhibiting interleukin‐4 and interleukin‐13 signalling, two central drivers of type‐2 (T2) inflammation. It is currently approved by both the Food and Drug Administration and the European Medicines Agency for multiple indications, including moderate‐to‐severe atopic dermatitis (from 6 months of age), add‐on maintenance therapy for moderate‐to‐severe asthma with T2 inflammation (≥ 6 years), eosinophilic esophagitis (≥ 1 year and ≥ 15 kg), chronic rhinosinusitis with nasal polyps (≥ 12 years in the United States and ≥ 18 years in Europe), and chronic spontaneous urticaria (≥ 12 years in the United States and ≥ 2 years in Europe) who remains symptomatic despite antihistamine therapy. Additional adult indications include prurigo nodularis, bullous pemphigoid, and chronic obstructive pulmonary disease with an eosinophilic phenotype. Beyond these established indications, increasing evidence suggests a broader therapeutic potential for dupilumab in paediatric diseases characterized by T2 immune dysregulation. This narrative review synthesizes the emerging literature on off‐label and investigational paediatric uses of dupilumab, focusing on inflammatory skin diseases, inborn errors of immunity with severe atopic phenotypes, transplant‐associated immune dysregulation, selected respiratory conditions and food allergy. Although current evidence largely derives from case reports, small case series, and observational studies, reported outcomes consistently indicate significant improvements in disease severity, and quality of life, with a favourable safety profile. These findings highlight the expanding role of IL‐4/IL‐13 blockade in paediatrics and underscore the need for prospective studies to better define efficacy, long‐term safety, and optimal patient selection in emerging indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Unit, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
- Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain.
- Immuno-Allergology Laboratory of Clinical Chemistry and Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Pediatric Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, Messina, Italy.
- Dermatologic Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
ORCID-Profile: Simone Foti Randazzese, Esther Mesa Lombardero, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia
Zitieren
APA
Foti Randazzese, S., Calamita, A., D'Angelo, D., Marseglia, A., Mesa Lombardero, E., Pedersoli, S., Tedeschi, M., De Amici, M., Manti, S., Brazzelli, V., Licari, A., & Marseglia, G. L. (2026). Emerging Paediatric Uses of Dupilumab Beyond Approvals. Clinical & Experimental Allergy, 56(10), 1162-1176. https://doi.org/10.1111/cea.70381
Vancouver
Foti Randazzese S, Calamita A, D'Angelo D, Marseglia A, Mesa Lombardero E, Pedersoli S, et al. Emerging Paediatric Uses of Dupilumab Beyond Approvals. Clinical & Experimental Allergy. 2026;56(10):1162-1176. doi:10.1111/cea.70381
BibTeX
@article{FotiRandazzese2026,
author = {Foti Randazzese, Simone and Calamita, Anna and D'Angelo, Diletta and Marseglia, Alessia and Mesa Lombardero, Esther and Pedersoli, Sara and Tedeschi, Micol and De Amici, Mara and Manti, Sara and Brazzelli, Valeria and Licari, Amelia and Marseglia, Gian Luigi},
title = {Emerging Paediatric Uses of Dupilumab Beyond Approvals},
journal = {Clinical & Experimental Allergy},
year = {2026},
volume = {56},
number = {10},
pages = {1162--1176},
doi = {10.1111/cea.70381}
}
EUVIMED